Research programme: anti-CD63 antibodies - Genentech

Drug Profile

Research programme: anti-CD63 antibodies - Genentech

Alternative Names: AR1A245.6; AR7BD-33-11A; ARH460-22-1; CD63 programme - ARIUS/Genentech

Latest Information Update: 29 Sep 2008

Price : $50

At a glance

  • Originator ARIUS Research
  • Developer Genentech
  • Class Monoclonal antibodies
  • Mechanism of Action Lysosomal protein GP53 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 24 Sep 2008 ARIUS Research has been acquired by Roche
  • 20 Mar 2008 Preclinical development is ongoing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top